Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TAK 
Takeda Pharmaceutical Co Ltd ADR (TAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $17.22
Year Target Price $17.22
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.24% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 48.29B USD | Price to earnings Ratio 64.42 | 1Y Target Price 17.22 |
Price to earnings Ratio 64.42 | 1Y Target Price 17.22 | ||
Volume (30-day avg) 4 | Beta 0.26 | 52 Weeks Range 12.76 - 15.48 | Updated Date 07/1/2025 |
52 Weeks Range 12.76 - 15.48 | Updated Date 07/1/2025 | ||
Dividends yield (FY) 4.32% | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.36% | Operating Margin (TTM) 11.68% |
Management Effectiveness
Return on Assets (TTM) 2.4% | Return on Equity (TTM) 1.52% |
Valuation
Trailing PE 64.42 | Forward PE 14.9 | Enterprise Value 75469489144 | Price to Sales(TTM) 0.01 |
Enterprise Value 75469489144 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 2.41 | Enterprise Value to EBITDA 10.26 | Shares Outstanding 3123680000 | Shares Floating 1572673983 |
Shares Outstanding 3123680000 | Shares Floating 1572673983 | ||
Percent Insiders 0.01 | Percent Institutions 2.3 |
Analyst Ratings
Rating 2 | Target Price 17.22 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Takeda Pharmaceutical Co Ltd ADR
Company Overview
History and Background
Takeda Pharmaceutical was founded in 1781 in Osaka, Japan. It has evolved from a traditional medicine vendor to a global, values-based, R&D-driven biopharmaceutical leader. Key milestones include international expansion and major acquisitions like Millennium Pharmaceuticals and Shire.
Core Business Areas
- Gastroenterology: Focuses on treatments for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
- Rare Diseases: Develops therapies for rare genetic and hematologic disorders, as well as immunodeficiency diseases.
- Plasma-Derived Therapies (PDT): Collects plasma to manufacture medicines for various conditions, including immunodeficiencies and bleeding disorders.
- Oncology: Develops treatments for various cancers, focusing on hematologic malignancies and solid tumors.
- Neuroscience: Offers treatments for neurological and psychiatric disorders like ADHD, depression, and narcolepsy.
Leadership and Structure
Takeda is led by Christophe Weber (President & CEO). The organizational structure is divided into global business units aligned with its core therapeutic areas, supported by global functions like R&D and commercial operations.
Top Products and Market Share
Key Offerings
- Entyvio: An integrin receptor antagonist for inflammatory bowel disease (IBD). It holds a significant market share in the IBD biologics market. Competitors include AbbVie (Humira, Skyrizi), Janssen (Stelara), and Pfizer (Xeljanz). Global sales are around $5.3 Billion USD.
- Vyvanse/Elvanse/Advanz: A stimulant medication for ADHD. Market share varies by region, but it's a leading ADHD treatment. Competitors include Teva (generic versions of ADHD medications), Johnson and Johnson (Concerta), and Eli Lily (Strattera). Sales were $2.5 Billion USD prior to patent expiration in some markets.
- Immunoglobulin Products: A range of plasma-derived therapies for immune deficiencies. Takeda is a major player in the immunoglobulin market. Competitors include CSL Behring and Grifols.
- Livtencity: An antiviral medication to prevent post-transplant cytomegalovirus infection. Competitors include F. Hoffman La Roche's Valcyte and Astellas's Prodraf.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Trends include personalized medicine, digital health, and increasing focus on biologics and specialty drugs.
Positioning
Takeda is positioned as a global biopharmaceutical leader with a focus on innovative therapies in its core therapeutic areas. Its competitive advantages include its R&D capabilities, global reach, and expertise in plasma-derived therapies.
Total Addressable Market (TAM)
The global pharmaceutical market is valued at approximately $1.48 trillion in 2022 and is projected to reach $1.9 trillion by 2028. Takeda is positioned to capture a significant portion of this TAM by focusing on its key therapeutic areas and expanding its global presence.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global presence and distribution network
- Expertise in plasma-derived therapies
- Focus on innovative therapies
- Experienced management team
Weaknesses
- High debt burden from the Shire acquisition
- Reliance on key products
- Exposure to generic competition
- Complexity of integrating acquired businesses
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Leveraging digital health technologies
- Strategic partnerships and collaborations
Threats
- Increasing competition from generic and biosimilar drugs
- Pricing pressures from governments and payers
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- ABBV
- NVS
Competitive Landscape
Takeda faces intense competition from other major pharmaceutical companies. Its advantages include its expertise in plasma-derived therapies and its focus on innovative therapies. Disadvantages include its high debt burden and reliance on key products.
Major Acquisitions
Shire
- Year: 2019
- Acquisition Price (USD millions): 62000
- Strategic Rationale: To expand Takeda's pipeline and global reach, particularly in rare diseases and gastroenterology.
Growth Trajectory and Initiatives
Historical Growth: Takeda's historical growth has been driven by organic growth in its core therapeutic areas and strategic acquisitions like Shire. Growth rates have fluctuated depending on product launches, patent expirations, and market conditions.
Future Projections: Future growth projections depend on factors like the success of its R&D pipeline, expansion into new markets, and the competitive landscape. Analyst estimates can vary.
Recent Initiatives: Recent initiatives include focusing on key therapeutic areas, divesting non-core assets, and investing in digital transformation.
Summary
Takeda is a global biopharmaceutical company with strengths in innovative therapies and plasma-derived products but faces high debt. Its R&D pipeline and global reach are advantages, but competition and debt management are challenges. Future growth hinges on successful product launches and strategic execution. They face generic competition and must adapt to healthcare regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Takeda Investor Relations
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Takeda Pharmaceutical Co Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2008-10-27 | President, CEO & Representative Director Mr. Christophe Weber | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 47455 | Website https://www.takeda.com |
Full time employees 47455 | Website https://www.takeda.com | ||
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.